Date: September 14, 2021

ATTN: Medical Health Officers and Branch Offices
      Public Health Nursing Administrators and Assistant Administrators
      Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
      Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine BNT162b2 (Pfizer)

The product page has been revised as follows:

- **Doses and Schedules:**
  - Content has been added regarding the provision of a third dose of a COVID-19 mRNA vaccine to individuals who are severely immunosuppressed for completion of a 3-dose primary vaccine series. Moderna COVID-19 vaccine is preferentially recommended for the third dose, however if unavailable, the Pfizer-BioNtech COVID-19 vaccine may be provided.

  
  Please remove page numbers: 1-6 dated August 31, 2021
  Please add new page numbers: 1-6 dated September 14, 2021

COVID-19 mRNA Vaccine mRNA-1273 (Moderna)

The product page has been revised as follows:

- **Doses and Schedules:**
  - Content has been added regarding the provision of a third dose of a COVID-19 mRNA vaccine to individuals who are severely immunosuppressed for completion of a 3-dose primary vaccine series. Moderna COVID-19 vaccine is preferentially recommended for the third dose, however if unavailable, the Pfizer-BioNtech COVID-19 vaccine may be provided.

  Please remove page numbers: 1-4 dated August 31, 2021
  Please add new page numbers: 1-5 dated September 14, 2021
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)

The product page has been revised as follows:

- **Doses and Schedules:**
  - Content has been added regarding the provision of a third dose of a COVID-19 mRNA vaccine to individuals who are severely immunosuppressed for completion of a 3-dose primary vaccine series. Moderna COVID-19 vaccine is preferentially recommended for the third dose, however if unavailable, the Pfizer-BioNtech COVID-19 vaccine may be provided.

  Please remove page numbers: 1-4 dated June 18, 2021
  Please add new page numbers: 1-5 dated September 14, 2021

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

The product page has been revised as follows:

- **Doses and Schedules:**
  - Content has been added to include the provision of an additional dose of a COVID-19 mRNA vaccine to individuals who are severely immunosuppressed and received Janssen COVID-19 vaccine for completion of a 2-dose primary vaccine series. Moderna COVID-19 vaccine is preferentially recommended for the second dose, however if unavailable, the Pfizer-BioNtech COVID-19 vaccine may be provided.

  Please remove page numbers: 1-4 dated June 3, 2021
  Please add new page numbers: 1-4 dated September 14, 2021

Influenza Vaccines

Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV) FLUZONE® HIGH-DOSE QUADRIVALENT

The product page has been revised as follows:

- **Precautions:**
  - Severe oculo-respiratory syndrome (ORS) after a previous dose of influenza vaccine has been added.

  Please remove page numbers: 1-2 dated August 2021
  Please add new page numbers: 1-2 dated September 2021
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division